Letters to the Editor

Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial

Laboratory of Hematology, CHU Lille, INSERM UMR-S 1277, Lille, France;
Laboratory of Hematology, CHU Lille, INSERM UMR-S 1277, Lille, France;
Laboratory of Hematology, CHU Lille, INSERM UMR-S 1277, Lille, France;
Pediatric Hematology Department, CHU Lille, Lille, France;
Pediatric Hematology and Oncology Department, CHU Bordeaux, France;
Pediatric Hematology and Oncology Department, CHU Rennes, France;
Pediatric Hematology and Immunology Department, CHU Toulouse, France;
Pediatric Hematology Department, AP-HP Robert Debré Hospital, Paris, France;
Pediatric Hematology Department, CHU Rouen, France;
Institute of Hematology and Pediatric Oncology, Lyon 1 University, Hospices Civils de Lyon, France;
Pediatric,Hematology,Oncology, Timone Enfants Hospital,Aix-Marseille University, Marseille, France;
Dept. Pediatric,Hematology,Oncology, Armand Trousseau Hospital, Sorbonne University, Paris, France;
Laboratory of Hematology, Armand Trousseau Hospital, Sorbonne University, Paris, France;
Laboratory of Hematology, CHU Lille, INSERM UMR-S 1277 - 9020 CNRS, Lille, France
Dept. Pediatric,Hematology,Oncology, Armand Trousseau Hospital, Sorbonne University, Paris, France;
Haematologica Early view Jun 18, 2020 https://doi.org/10.3324/haematol.2020.248872